In 1998, Fred Hutch’s Cancer Biology Program merged with the Division of Molecular Medicine and an initiative in genetics/genomics to create the Human Biology Division. Since then, we’ve performed ongoing laboratory-based and computational research, driving the translation of research into life-saving treatments.
Researchers work across divisions to increase our knowledge base of genetic profiles and epidemiology. Our studies focus on breast, cervical, ovarian, prostate and esophageal cancers, as well as non-solid tumors and infectious diseases that influence cancers. The more we learn about the relationships between human biology and these diseases, the better we’ll be able to prevent, diagnose and treat cancer.
We’re committed to nurturing the scientific process while working across the continuum of research from basic to clinical, from infectious disease to cancer. Our scope is broad, but our relatively small size allows us to stay agile and be responsive to new ideas. To maintain a legacy of world-class research, our senior faculty are accessible to student scientists and mentoring is a priority.
The Immunotherapy Integrated Research Center (IIRC) creates a partnership across the Hutch in cell therapy, transplant immunology, tumor microenvironment, immune checkpoint regulation, immunogenomics, therapeutic vaccines and more, to develop the next generation of immune-based lifesaving therapies.
The Pathogen-Associated Malignancies Integrated Research Center (PAM IRC) combines research in infectious diseases, host-pathogen interactions, cancer biology, immunology, global oncology and immunotherapy to understand, treat and prevent cancers linked to infectious agents.